<DOC>
	<DOCNO>NCT02627950</DOCNO>
	<brief_summary>The current prospective , randomize , control MonAMI trial aim systematically examine effect morphine platelet inhibitory effect orally administer platelet inhibitor ticagrelor patient acute myocardial infarction . In addition , potential positive negative effect MCP combination morphine platelet inhibition study .</brief_summary>
	<brief_title>Impact Morphine Treatment Platelet Inhibition Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . STelevation myocardial infarction &lt; 24 h symptom onset nonSTelevation myocardial infarction persistent chest pain &lt; 24 h symptom onset 2 . Intended revascularization primary percutaneous coronary intervention 3 . Informed consent 4 . Age â‰¥18 year 1 . Age &lt; 18 year 2 . Active bleed bleed diathesis 3 . Oral anticoagulation 4 . Current treatment clopidogrel/prasugrel/ticagrelor/glycoproteinIIbIIIareceptorantagonists 5 . Current treatment morphine and/or MCP &lt; 12 h 6 . Contraindication treatment platelet inhibitor 7 . Fibrinolysis &lt; 48 h 8 . Percutaneous coronary intervention coronary artery bypass graft &lt; 3 month 9 . Known glomerular filtration rate &lt; 30 ml/min 10 . Severe liver dysfunction 11 . Hypersensitivity ticagrelor excipients 12 . History intracranial hemorrhage 13 . Known pregnancy , breastfeed intend become pregnant study period 14 . Participation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>